Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
Clinical trial NCT02598297 · TERMINATED
Trial details
- NCT number
- NCT02598297
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-03
- Primary completion
- 2017-10-23
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.